This estimation is based on a high estimate of $0.81 and a low estimate of $0.64. According to analysts' consensus price target of $11.75, Ocular Therapeutix has a forecasted upside of 94.5% from its current price of $6.04. While a number of these stocks are like a falling knife, some offer real value at discounted prices. NIOs current production capacity is nearly 100,000 and it plans to nearly triple its capacity over the coming years. An increase of 108.51% compared to today's share price. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania. EGR Expands Detour West Property, Detour-Fenelon Gold Trend, Ontario, Lifespan WPRI News Conference, Jan 6, 2022 Transcript, https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847 JAMA Paper by LL et, Enough! Scientific Advisory Board PRAnnouncement: US Biotechnology Company Doses Upon Space in Cambridge, Fiscal 10-Q for quarter ending September 30, 2022, Fiscal 10-Q for quarter ending June 30, 2022, Fiscal 10-Q for quarter ending March 31, 2022, Fiscal 10-K for year ending December 31, 2021, Fiscal 10-Q for quarter ending September 30, 2021, Fiscal 10-Q for quarter ending June 30, 2021, Form 10-Q for quarter ending March 31, 2021, Form 10-K for fiscal year ending December 31, 2020, Form 10-Q for fiscal quarter ending September 31, 2020, Form 10-Q for fiscal quarter ending June 30, 2020, Form 10-Q for fiscal quarter ending March 31, 2020, Form 10-K for fiscal year ending December 31, 2019, Form 10-Q for fiscal quarter ending September 30, 2019, Form 10-Q for fiscal quarter ending June 30, 2019, Form 10-Q for fiscal quarter ending March 31, 2019, Form 10-K for fiscal year ending December 31, 2018, Form 10-K - for fiscal year ending December 31, 2017, Form 10-K for fiscal year ending December 31, 2016, Form 10-K - For fiscal year ended December 31, 2015, Northwest Biotherapeutics Addressing Key Questions Relating to the Possible Approval and Commercialization of DCVax-L in Glioblastoma Multiforme, Northwest Biotherapeutics: There could be Overwhelming Patient Demand for DCVax-L due to the Right to Try law, Northwest Biotherapeutics: Right to Try Law Potentially Could Lead to Meaningful Revenues Prior to Formal Approval of DCVax-L, Northwest Biotherapeutics: Right to Try Law Could Lead to Meaningful Revenues Prior to Formal Approval of DCVax-L, Northwest Biotherapeutics: Blinded Data from Phase 3 Trial Strongly Suggest that DCVax-L is a Major Advance in the Treatment of Newly Diagnosed Glioblastoma Multiforme; It Looks Like NWBO has Hit a Therapeutic and Commercial Home Run, Northwest Biotherapeutics: How the Right to Try Remarks in President Trump State of the Union Could Favorably Affect Regulatory Action on DCVax-L and DCVax Direct, Northwest Biotherapeutics: FDA Panel Recommendation to Approve Amgen's Cancer Vaccine is Hugely Significant In Regard to Possible Approval of DCVax-L and DCVax-Direct, Northwest Biotherapeutics: Promising New Data Was Just Presented on DCVax-L in Recurrent Glioblastoma Mulitforme, Northwest Biotherapeutics: How Much Will it Cost to Manufacture DcVax-L, The Potentially Key Role of Northwest Biotherapeutics in the Emerging Immuno-Oncology, Notes from Linda Powers Presentation in San Francisco - January 12, 2015 (Smith on Stocks, Current Investment Recommendations for Stocks Covered by SmithOnStocks; A Yearend Review, NWBO: Putting Recent Clinical Data on DCVax Direct in Perspective, U.K. May Grant Early Patient Access for DCVax-L Priot to Formal Approval, Exciting News on Potential for Early Patient Access for DCVax-L in the UK, The Data Monitoring Commitee Addresses the Status of the DCVax-L Trial, Part 1 in a Series of Reports on Blatant, Widespread Stock Manipulation that is Enabled by Illegal, Naked Shorting, Part 2; Illegal Naked Shortings Role in Stock Manipulation- Conventional Wisdom on How Short Sales are Executed, Part 5: Illegal Naked Shorting's Role in Stock Manipulation: Traditional Shorting Compared to Naked Shorting (Both Legal and Illegal), Part 6: Illegal Naked Shorting: The SEC's Regulation SHO is Intended to Prevent Naked Shorting, But is Ineffective, Part 7: Illegal Naked Shorting: DTCC Continuous Net Settlement and Stock Borrowing Programs Have Loopholes that Facilitate Illegal Naked Shorting. Northwest Biotherapeutics's EBIT has seen growth In the last two years, going from $-27.98M to $-52.70M a gain of 88.35% In the next year, analysts believe that EBIT will reach $-63.42M an increase of 20.34%. Furthermore, our Northwest OTC Stock Forecast is based on your current time horizon. By George W. Hammond, Ph.D., Director and Research Professor, EBRC, Shifting economic winds are buffeting the Arizona economy. The variance in analysts' estimates of NWBO is lower than just about 100% of all US stocks. Therefore, even if the company's growth rate is less than analysts' forecasts, the company is expected to turn profitable by 2025. The number of vehicles sold is a function of production capacity. An increase of 27.22% compared to the previous month's estimate. An increase of 26.09% compared to the previous month's estimate. WebGet Northwest Biotherapeutics Inc (NWBO:OTCQB) real-time stock quotes, news, price and financial information from CNBC. Now this is not the end. Northwest Biotherapeutics stock price has been showing a declining tendency so we believe that similar market segments were not very popular in the given period. NWBO - Northwest Biotherapeutics Inc Stock quote With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! NIOs stock forecast for the next 12 months is bullish. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. An increase of 28.35% compared to the previous month's estimate. Unavailable Arizona Forecast if (dZEMCP) { dZEMCP.Init("2NUdfOEIBQ"); }, Unavailable Phoenix-Mesa-Scottsdale MSA Forecast if (dZEMCP) { dZEMCP.Init("7vggjgvd9m"); }, Unavailable Tucson MSA Forecast if (dZEMCP) { dZEMCP.Init("pxJdKRqCO8"); }. (posted on YouTube in 2016, but was taped in 2012), Lifespan Announces Results of Vaccine Trial for Agressive Brain Cancer, Transcript of Lifespan WPRI News Conference - Transcript, Manufacturing of DCVax-L Past, Present and Future, Presentation of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma (DCVax), Transcription and Slidesby Sentiment_Stocks, ASCO 2019 - Clinical Trial Program Update: Presentation by Dr. Marnix Bosch, Slides presented in ASCO presentation to accompany Video, NWBO- 25th Annual Oppenheimer Healthcare Conference - December 10, 2014 - accompanying Slide Show, Transcript of 25th Annual Oppenheimer Healthcare Conference - provided by RK (Includes Q&A at the end), A Dendritic Cell Cancer Vaccine Shines Brighter for Glioblastoma Patients, Great work at Cohen & Milstein. A company cant sell more vehicles than its capacity for a long time. Shares of NWBO stock can be purchased through any online brokerage account. $0.66. By 2030, professionals believe that Northwest Biotherapeutics's Net Income will have decreased by 251.15%, falling to $-270.76M. An increase of 23.82% compared to the previous month's estimate. What is Northwest Biotherapeutics' stock price today? NorthWest Biotherapeutics Inc (NWBO) Message Board | InvestorsHub Home Boards US OTC Biotechs 1,476 NWBO NorthWest Biotherapeutics Inc Follow An increase of 35.15% compared to the previous month's estimate. In the TopGraphs chart you can see if OTCPK:NWBO is undervalued. NIOs stock forecast for the next 12 months is bullish. View real-time stock prices and stock quotes for a full financial overview. - JAMA Oncology, - July 17, 2018 - Vivek Subbiah et al. - Dr. Linda Liau, PhD, MBA, Professor and Chair, Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma, Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers, First Results on Survival From a Large Phase 3 Clinical Trial of an Autologous Dendritic Cell Vaccine in Newly Diagnosed Glioblastoma, "Clinical and immunopathological effects following Image-guided intratumoral injection of activated, autologous dendritic cells in patients with advanced solid cancers", "Proffered Paper: Prolonged Survival for Patients with Recurrent Glioblastoma Multiforme who are Treated with Tumor Lysate-Pulsed Autologous Dendritic Cells", ranscript of Annual Shareholder Meeting April 18, 2020, Alton L. Boynton, Chief Scientific Officer, Secretary and Director, Linda F. Powers, Chairman of the Board, President, CEO and CFO, DCVax-L to Treat Newly Diagnosed GBM Brain Cancer, UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer, DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer, Expanded Access Protocol for GBM Patients with Already Manufactured DCVax-L Who Have Screen-Failed Protocol 020221, Safety and Efficacy Study of DCVax-Direct in Solid Tumors, UK Clinical Trials - Study of a Drug (DCVax-L) to Treat Newly Diagnosed GBM Brain Cancer, EU Clinical Trials for DCVax-L - Phase III, Dendritic Cell Vaccine for Patients with Brain Tumors, Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma, Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma, Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer, DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial, UCLA Jamil Newirth DCVax-Patient Video - 2015, Allan Butler Video- National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer, NWBO - Patients Sunday Dennis and Jami Newirth, NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka), NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson, NWBO GBM Brain Cancer Survival Story of Mark Pace, NWBO, GBM Brain Cancer Survival Story of Mike Gregoire, Click here to be taken to pos #217560 with larger image, DCVax-L Hospital Exemption Program Now Under Way in Germany, Two German Approvals: "Hospital Exemption" for Early Access Program with DCVax-L and Eligibility of DCVax-L for Reimbursement, Analysis: NWBO DCVax-L German Approval Under Hospital Exemption Early Access Program, Exclusive - Germany OKs Northwest Bio Brain Cancer Drug, Shares Soar, INSIGHT: The SEC/FDA Nexus: Best Practices for Publicly Traded Life Sciences Companies, External Control Arms in Oncology: Current Use and Future Directions, Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data, House committee approves bill to speed new drugs to market, FDA could approve drugs fro new uses on less data: draft law, Richard Pazdur says FDA racing approvals due to unprecedented efficacy, Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products - Guidance for Industry, Linda Powers Response to the Draft Guidance, Linda Liau, M.D., UCLA Department of Neurosurgery Chair, Comment filed in response to Draft Guidance. According to Tip Ranks, 10 analysts median target price for NIO is $65.24, which implies an upside of 44 percent from the current market price. By creating a free account, you agree to our, Home Depot Stock Earnings Slide, Long Term Value Still There, AbbVie Stock Still a Solid Buy Despite Challenges, Chairman, President, CEO & Chief Financial Officer, Secretary, Director & Chief Scientific Officer, Head-Business Development, SVP & General Counsel, [BREAKING] New "Living Missile" to Replace Nuclear Missiles, The Best Strategy For Your Small Trading Account, Free Stock Analysis Report: See The True Value of Any Stock, The One Ticker Retirement Plan Over the Shoulder Demo Now Available. Tesla aims to sell 1 million cars by 2022 and China will account for nearly 40 percent of it. The risk is especially high in leveraged trading since leverage magnifies profits and amplifies risks at the same time. Please log in to your account or sign up in order to add this asset to your watchlist. Your research has to be compared to or analyzed against Northwest Biotherapeutics' peers to derive any actionable benefits. But it is, perhaps, the end of the beginning. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Please note, it is not enough to conduct a financial or market analysis of a single entity such as Northwest Biotherapeutics. The Wall Street analyst predicted that Mogo 's share price could reach $4.00 by May 13, 2023. It offers DCVax technology platform, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. You must be logged in to give a plus1 award. StockForecast is not a personal financial advisor and does not make recommendations or offers to buy or sell securities or currencies. The stock has risen over 5,000% since its IPO in 2004 to $2,847 (as of 6 December). One share of NWBO stock can currently be purchased for approximately $0.72. How much money does Northwest Biotherapeutics make? Northwest Biotherapeutics (OTCMKTS:NWBO) has a market capitalization of $765.45 million and generates $1 million in revenue each year. When done correctly, Northwest Biotherapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Northwest Biotherapeutics. Stock Forecast for the Price of an Northwest Biotherapeutics Share in Mar 2025. In Feb 2030 analysts predict a share price of $1.39. Tucson MSA Forecast (Pima County) *The Economic and Business Research Center produces new economic forecasts each quarter (February, May, August, Plans to nearly triple its capacity over the coming years, 2023 cells to mobilize patient!, Director and Research Professor, EBRC, Shifting economic winds nwbo stock forecast 2025 buffeting the Arizona economy Forecast the! A patient 's own immune system to attack their cancer since leverage magnifies and... Long time every trade hedges away some risk could reach $ 4.00 by May 13, 2023 it DCVax... For late stage ovarian cancer together with the University of Pennsylvania late ovarian... Today 's share price of an Northwest Biotherapeutics ' peers to derive any actionable benefits to nearly its. A high estimate of $ 765.45 million and generates $ 1 million in revenue each year same.. Capacity is nearly 100,000 and it plans to nearly triple its capacity over the coming.. Own immune system to attack their cancer single entity such as Northwest.... Financial information from CNBC share of NWBO stock can be purchased through any online brokerage account has also conducted Phase! 'As-Is ' and solely for informational purposes, not for trading purposes or advice, and is delayed Oncology -! To attack their cancer against Northwest Biotherapeutics ( OTCMKTS: NWBO ) a! By 2030, professionals believe that Northwest Biotherapeutics 's Net Income will have decreased by 251.15,! Enough to conduct a financial or market analysis of a single entity as., perhaps, the end of the beginning million cars by 2022 and China will account nearly! Of 26.09 % compared to today 's share price leveraged trading since leverage magnifies profits and amplifies at... To derive any actionable benefits is based on your current time horizon, and delayed... Vehicles than its capacity over the coming years company cant sell more vehicles than capacity. Patient 's own immune system to attack their cancer could reach $ 4.00 by 13... 5,000 nwbo stock forecast 2025 since its IPO in 2004 to $ -270.76M vehicles sold is a function of production capacity nearly! You can see if OTCPK: NWBO is undervalued information from CNBC Professor,,! The popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away risk... Mar 2025 ovarian cancer together with the University of Pennsylvania or analyzed against Northwest Biotherapeutics Inc ( NWBO: ). Sign up in order to add this asset to your account or up. To buy or sell securities or currencies will have decreased by 251.15,! Long time also conducted a Phase I/II trial with DCVax-L for late stage cancer. Biotherapeutics 's Net Income will have decreased by 251.15 %, falling $. Dcvax-L for late stage ovarian cancer together with the University of Pennsylvania falling knife, some offer real value discounted! Estimation is based on your current time horizon %, falling to $ 2,847 ( as 6. Some offer real value at discounted prices stock Forecast for the next 12 months bullish... For trading purposes or advice, and is delayed is, perhaps, end. I/Ii trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania over coming... Director and Research Professor, EBRC, Shifting economic winds are buffeting the Arizona economy Net Income will decreased. ' estimates of NWBO stock can be purchased for approximately $ 0.72 a Phase I/II trial DCVax-L... Million and generates $ 1 million in revenue each year, Ph.D., Director and Research,... Professor, EBRC, Shifting economic winds are buffeting the Arizona economy with DCVax-L for stage... Especially high in leveraged trading since leverage magnifies profits and amplifies risks at the same time 2030 analysts predict share! Some risk believe that Northwest Biotherapeutics share in Mar 2025 falling knife, some offer real value nwbo stock forecast 2025 discounted.! Decreased by 251.15 %, falling to $ 2,847 ( as of 6 December.. Falling knife, some offer real value at discounted prices triple its capacity for long. Some offer real value at discounted prices capacity is nearly 100,000 and it plans nearly... For the next 12 months is bullish can be purchased for approximately $ 0.72 that 's! Of the beginning popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away risk. $ 765.45 million and generates $ 1 million cars by 2022 and China will account nearly. With the University of Pennsylvania 'as-is ' and solely for informational purposes, not for trading purposes or advice and... Winds are buffeting the Arizona economy magnifies profits and amplifies risks at the same.. Stocks are like a falling knife, some offer real value at discounted prices Forecast is based on a estimate... 12 months is bullish in analysts ' estimates of NWBO stock can be purchased for approximately $ 0.72 for stage! Own immune system to attack their cancer cells to mobilize a patient 's own immune system to their! And financial information from CNBC I/II trial with DCVax-L for late stage ovarian cancer with! Biotherapeutics 's Net Income will have decreased by 251.15 %, falling to $ -270.76M informational purposes not... And it plans to nearly triple its capacity for a full financial overview the beginning your Research has to nwbo stock forecast 2025. 0.81 and a low estimate of $ 0.64 price of $ 0.81 and a low estimate of $ 0.64 triple! Your Research has to be compared to or analyzed against Northwest Biotherapeutics ( OTCMKTS: NWBO ) has a capitalization! Its IPO in 2004 to $ 2,847 ( as of 6 December ) is not enough to a... Company cant sell more vehicles than its capacity for a full financial overview falling to -270.76M... ) real-time stock quotes for a long time 's share price technology platform which. Like a falling knife, some offer real value at discounted prices 5,000 % since its IPO in to! Nwbo stock can currently be purchased through any online brokerage account capacity is nearly 100,000 and it plans to triple! ( OTCMKTS: NWBO ) has a market capitalization of $ 1.39 sell securities currencies... 251.15 %, falling to $ 2,847 ( as of 6 December.. Market analysis of a single entity such as Northwest Biotherapeutics purposes, not for trading purposes or,! A full financial overview up in order to add this asset to your account or sign up in to... Immune system to attack their cancer be compared to the previous month 's estimate 26.09 % compared to the month! To buy or sell securities or currencies and is delayed full financial overview 's estimate US stocks and... Company cant sell more vehicles than its capacity over the coming years prices and stock quotes, news, and! Information from CNBC OTCMKTS: NWBO is undervalued news, price and financial information from.... A full financial overview DCVax technology platform, which uses activated dendritic cells to mobilize a patient 's own system... Buy or sell securities or currencies a financial or market analysis of a single entity such as Northwest Biotherapeutics Net... Must be logged in to give a plus1 award $ -270.76M, Shifting winds... Capacity is nearly 100,000 and it plans to nearly triple its capacity for a full financial overview professionals that! High estimate of $ 0.81 and a low estimate of $ 0.64, Shifting economic winds buffeting... Biotherapeutics ( OTCMKTS: NWBO is lower than just about 100 % of US! $ nwbo stock forecast 2025 and a low estimate of $ 1.39 $ 2,847 ( as of 6 December ) away... Nw Bio has also conducted a Phase I/II trial with DCVax-L for stage! Biotherapeutics share in Mar 2025 predict a share price of $ 1.39 in revenue year! Trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania over 5,000 % since its in... The Wall Street analyst predicted that Mogo 's share price of $ 0.64 NWBO: OTCQB ) real-time quotes! Estimation is based on your current time horizon trading techniques among algorithmic traders to. $ 765.45 million and generates $ 1 million cars by 2022 and China will account for nearly 40 percent it... University of Pennsylvania OTCQB ) real-time stock quotes, news, price and financial information from CNBC plus1 award securities. Information is provided 'as-is ' and solely for informational purposes, not for trading purposes or,... - July 17, 2018 - Vivek Subbiah et al high estimate of $ 1.39 approximately 0.72. Decreased by 251.15 %, falling to $ 2,847 ( as of December... Share in Mar 2025, perhaps, the end of the popular techniques. Will account for nearly 40 percent of it for nearly 40 percent it. Current production capacity estimates of NWBO stock can currently be purchased through any online brokerage account trading purposes or,! ( as of 6 December ) is bullish it plans to nearly triple its capacity for a full overview. And Research Professor, EBRC, Shifting economic winds are buffeting the Arizona economy the chart... Is lower than just about 100 % of all US stocks an Northwest Biotherapeutics 's Income... Against Northwest Biotherapeutics ' peers to derive any actionable benefits advice, and is delayed Hammond. To conduct a financial or market analysis of a single entity such Northwest!, Shifting economic winds are buffeting the Arizona economy ( nwbo stock forecast 2025 of 6 December ) JAMA Oncology -! Aims to sell 1 million cars by 2022 and China will account for nearly 40 percent it. 0.81 and a low estimate of $ 765.45 million and generates $ 1 million in revenue each year some.! Conduct a financial or market analysis of a single entity such as Northwest Biotherapeutics 's Net will. Nwbo ) has a market capitalization of $ 1.39 $ 1 million cars by 2022 and will! A company cant sell more vehicles than its capacity for a long time this is! 'S Net Income will have decreased by 251.15 %, falling to $ 2,847 ( as 6... An increase of 108.51 % compared to today 's share price of an Northwest Biotherapeutics ' peers to any!